Sanofi Gets CDSCO Panel Nod to Update Aldurazyme Prescribing Information
New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to Sanofi Healthcare India Pvt Ltd to update the prescribing information (Version dated December 2024) for its enzyme replacement therapy, Aldurazyme (Laronidase for Solution for Injection 2.9 mg/5 mL).
This approval follows Sanofi’s submission seeking alignment of the Indian prescribing information with the US Prescribing Information (USPI) dated December 2023.
Aldurazyme, which contains the active ingredient laronidase, is used for enzyme replacement therapy in patients with Mucopolysaccharidosis I (MPS I), a rare inherited disorder. It is administered intravenously and helps manage non-neurological symptoms such as enlarged liver, joint stiffness, and reduced lung function, which are caused by the accumulation of glycosaminoglycans (GAGs) in body tissues.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.